History & Objectives Team
2023 ILROG Conference Upcoming Meetings Past Meetings
Guidelines Publications Resources for Trainees Resident Elective IJROBP 2015 Special Edition Youtube
Membership Twitter Contact Ask an Expert!
 

Hodgkin Lymphoma

 

Non-Hodgkin Lymphoma

Critical Reading

Reduced Dose RT for Local Control in NHL

FORT Trial

RICOVER-60 NoRTh


Supplemental Reading

DLBCL

  1. DLBCL ACR Appropriateness Criteria 

  2. Re-examining the Role of RT for DLBCL in the Modern Era

  3. SWOG 8516: CHOP vs. Other Intensive Chemotherapy Regimens

  4. SWOG S8736 CHOP3 + RT vs. CHOP8

  5. LNH-98.5: CHOP vs R-CHOP 

  6. MInT: CHOP vs. R-CHOP

  7. IFRT vs INRT as Consolidation for DLBCL 

  8. LYSA trial: R-CHOP +/- RT

  9. Consolidative RT after R-CHOP: MDACC Experience

  10. Skeletal DLBCL 

  11. NCDB: Use of RT for DLBCL

  12. SEER: Use of RT for DLBCL

  13. PARMA: +/- ASCT for Relapsed NHL

  14. RT for Relapsed/Refractory DLBCL 

  15. DLBCL Subtypes by Gene Expression Profiling 

  16. Hans Algorithm: Classification of DLBCL Subtypes by Immunohistochemistry

  17. Reduction of the treated volume to INRT as part of CMT for early stage aggressive NHL

PMBCL

  1. NCI Phase 2 Trial: Dose-Adjusted R-EPOCH for PMBCL

  2. IELSG26: Response Assessment by PET in PMBCL

  3. Improved Survival with Combined Modality for PMBCL

  4. PET Guided Therapy for PMBCL

Primary CNS Lymphoma

  1. IELSG32 Phase 2 Trial: Consolidative WBRT vs. ASCT

  2. R-MPV + reduced dose WBRT: MSKCC Experience

Follicular Lymphoma

  1. LymphoCare: Patterns of Care for FL in the USA

  2. TROG 99.03: IFRT +/- R-CVP for FL

  3. Salvage Treatment and Survival for Relapsed FL Following Primary RT: Collaborative ILROG Study

  4. Definitive RT for localized FL staged by 18F-FDG PET-CT: Collaborative ILROG Study

Marginal Zone Lymphoma

  1. Gastric MALT Treated with RT Alone: MSKCC Experience

  2. Orbital MALT treated with low-dose RT: Stanford Experience

  3. Long-term outcome of early-stage extranodal marginal zone lymphoma: MSKCC Experience

  4. Long-term outcome of early-stage extranodal marginal zone lymphoma after RT: MSKCC Experience

Mantle Cell Lymphoma

  1. Early-stage MCL: A Retrospective Analysis from ILROG

  2. RT as an Effective Modality for MCL

  3. 4Gy as an Effective Treatment of MCL

Cutaneous Lymphoma

  1. Efficacy of 12 Gy TSEB 

  2. RT for Low-grade Cutaneous B-cell Lymphoma


Solitary Plasmacytoma

Rare Cancer Network Study: Solitary Plasmacytoma of Bone

Solitary Plasmacytoma: MDACC Experience


Leukemia

Chloroma: MSKCC Experience

 Cranial RT for CNS+ AML: University of Washington Experience

Craniospinal Irradiation for CNS+ Leukemia: MDACC Experience

 TBI Review 


RT Techniques

IMRT Butterfly Technique for Mediastinal Lymphoma

Cardiac Atlas


Long-Term Toxicity

Dose-response Relationship for Coronary Heart Disease in HL Survivors

Secondary Breast Cancer Risk by RT Volume in HL Survivors 

2013 - Prospective study of the efficacy of breast MRI and mammographic screening in survivors of HL


Imaging

Lugano Classification

Prospective Study of PET with CT Co-registration for RT Planning


Health Policy

2016 - Are Advanced RT Techniques Necessary for HL?


Editorials

2018 - Early-Stage FL: What Is the Preferred Treatment Strategy?

2018 - Progress in the Treatment of Hodgkin's Lymphoma

2018 - Balancing Risk and Benefit in Early-Stage cHL

2016 - Re-examining the Role of RT for DLBCL in the Modern Era

2014 - Limited-Stage Hodgkin Lymphoma: Managing Uncertainty

2014 - RT for Indolent Lymphomas: How Much is Enough?


Reviews

2020 - Hematologic Malignancies (Y Tseng, A Ng)

 
 

Interested in learning more?
Get in touch with us today